The heart failure treatment ‘Entresto’ will now be covered by insurance benefits in the first line as well.

According to industry sources, reimbursement for Novartis Korea’s chronic heart failure treatment ‘Entresto (sacubitril)’ will be expanded to cover patients with acute decompensated heart failure who are in a stable hemodynamic condition after hospitalization regardless of their administration of ACE inhibitors or angiotensin II receptor blockers from March 1st.

On the 14th, the authorities approved an additional indication for Entresto in patients with chronic heart failure whose left ventricular ejection fraction (LVEF) level is below normal to ‘reduce risk of cardiovasc